Abstract
BackgroundIn July 2013, the European Medicines Agency suspended the marketing authorisation of tetrazepam across the European Union due to serious cutaneous adverse drug reactions (ADR). Here we examine information described...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Hospital Pharmacy: Science and Practice
Paper Title
Journal
Date
